Oct. 1, 2019
by Andrii Buvailo
Biopharma insight
(This post first appeared in Forbes) Pioneered by expensive and cumbersome legacy electronic data interchange (EDI) systems, the B2B e-commerce …
Aug. 9, 2019
by Ximena Rodriguez
Biopharma insight
Pharmacogenomics seeks to understand underlying genetic markers that influence treatment responses and modification of therapies to increase efficacy treatment success …
July 25, 2019
by Tudor Oprea
Biopharma insight
About one in three human proteins is understudied. Even when quantifying data is available from multiple sources, "dark" genes and proteins …
July 24, 2019
by Jacob LaPorte
Biopharma insight
In a seminal work published by McKinsey & Company – The Granularity of Growth, a detailed study of the performance …
May 27, 2019
by David Shlaes
Biopharma insight
Over the past decade, pull incentives as a solution to the broken antibiotic market have been proposed to entice companies …
May 19, 2019
by Andrii Buvailo
Biopharma insight
Things like gene editing, stem cells, immunotherapies and new types of biologics are now mega-trends in the pharmaceutical industry, widely …
April 25, 2019
by Tim Sandle
Biopharma insight
Major companies on the scene include Second Genome, Enterome, and EpiBiome. In addition, several new startups have entered the field. …
Feb. 20, 2019
by Andrii Buvailo
Biopharma insight
In 1970-80s, the idea of virtual screening was regarded as a conceptual way to substitute costly and time-consuming experimental “screen-everything-you-have” …
Feb. 8, 2019
by Ben Ramsbottom
Biopharma insight
According to a research report by The Business Research Company, the global pharmaceuticals market was worth $934.8 billion in 2017. …
Jan. 15, 2019
by Naheed Kurji
Biopharma insight
In this Special Perspective, our fourth in an ongoing series, we will be presenting MatchMaker™, a novel deep proteome screening …
Jan. 10, 2019
by Andrii Buvailo
Biopharma insight
Updated: 10.01.2019. Newly added content is marked in the text with "Update" sign. The idea of using artificial intelligence (AI) …
Dec. 27, 2018
by David Shlaes
Biopharma insight
Antibiotic R&D has had a particularly bad year starting with The Medicines Company who abandoned their antibiotic R&D efforts and …